The Fed has cut rates with the S&P 500 at a record four times before. Here's what happened next

The Federal Reserve is widely expected to implement a quarter-point rate cut while the S&P 500 is at record highs, a historically rare scenario that JPMorgan notes has previously led to an average 20% benchmark return one year out. This unusual easing reflects the Fed unwinding post-pandemic tightening rather than combating an economic downturn, despite some labor market weakness. Consequently, strategists are identifying opportunities, with Citadel Securities recommending QQQ call options for late-year upside convexity, and Morgan Stanley highlighting healthcare, particularly biotech, as beneficiaries of rate cuts into 2026.

Analysis

The Federal Reserve is anticipated to implement a 25-basis-point rate cut this Wednesday, a historically rare event given the S&P 500's current record levels, closing at 6,890.89 on Tuesday and briefly surpassing 6,900. JPMorgan's analysis indicates only four prior instances of rate cuts with the S&P 500 at an all-time high, each leading to positive returns one year out, averaging 20% with a minimum of 15%.

This unusual easing reflects the Fed's strategy to unwind post-pandemic tightening measures, rather than responding to an economic downturn, despite some recent labor market weakness and a notable bifurcation in confidence between high and lower-income groups. The economy currently shows minimal signs of recession, distinguishing this period from typical rate-cutting cycles.

Strategists are identifying specific opportunities within this environment. Citadel Securities recommends buying Invesco QQQ Trust (QQQ) call options, specifically the $655 Nov. 28 and $670 Dec. 31 calls, citing attractive upside convexity amid easing financial conditions. Morgan Stanley highlights healthcare stocks, particularly biotech (IBB), as potential beneficiaries of rate cuts into 2026, noting strong relative performance 6-12 months post-initial cuts; the iShares Biotechnology ETF (IBB) has already surged 19.3% year-to-date.

Key Decisions for Investors

• Investors should consider tactical long positions, particularly in growth-oriented sectors like technology, potentially utilizing options strategies such as QQQ calls, given the historical precedent of strong market performance following similar rare Fed actions.
• Evaluate healthcare and biotechnology sectors for potential outperformance into 2026, aligning with Morgan Stanley's view on rate cut beneficiaries, especially given the iShares Biotechnology ETF's (IBB) recent strong performance.
• Monitor incoming economic data, particularly labor market trends and consumer confidence, as the Fed's current policy trajectory is predicated on unwinding prior tightening rather than addressing a weakening economy.